Posts Tagged: CTC

Blood_Liquid-Biopsy_700x233

Circulating tumor cell (CTC) biomarkers in liquid biopsy – not ready for prime time?

Currently, the only FDA-approved use of circulating tumor cells (CTCs) is identifying and counting CTCs in whole blood from patients with metastatic breast, colon or prostate cancer (1). Based upon recent developments, enumeration of CTCs is only the tip of the iceberg. Molecular characterization of CTCs would permit noninvasive genotyping in real time, potentially sampling… Read article →